In Brief: FDA radiation protection
This article was originally published in The Gray Sheet
Executive Summary
FDA radiation protection: Agency announces availability of up to $1.5 mil. in annual funds "for a period of five years, for the establishment of a cooperative agreement to support efforts to coordinate Federal and State actions to assure radiation protection of the American public," according to a June 19 Federal Register notice. Applications must be received by July 25...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.